Gulf Between U.S. and Europe's Climate Targets Just Got Wider
The European Commission, the EU's executive, said Wednesday it wants emissions in the bloc to decrease 90% by 2040 compared with 1990 levels. The commission's previous goal was for emissions to fall 55% by 2030.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
21 minutes ago
- Associated Press
China retaliates against EU with a ban on European medical devices
BANGKOK (AP) — China said Sunday that European medical device companies will be barred from selling to the Chinese government as a countermeasure for the European Union's restrictions on the sale of similar products from China. European companies will be excluded if the budget for procurement is above 45 million yuan ($6.28 million), according to a notice from the Finance Ministry on Sunday with the restrictions in place the same day. The move will not apply to European companies that have invested in China and that manufacture goods in the country. China on Friday imposed anti-dumping duties on European brandy, most notably cognac produced in France. While the duties on brandy include several exceptions for major brandy producers, China and the EU have multiple trade disputes across a range of industries. China protested after many European countries levied duties on EVs made in China. Since then, China has also launched investigations into European pork and dairy products. In June, the EU announced that Chinese companies were to be excluded from any government purchases of more than 5 million euros ($5.89 million). The measure seeks to incentivise China to cease its discrimination against EU firms, the EU said, accusing China of erecting 'significant and recurring legal and administrative barriers to its procurement market.' In response, China has said it had 'no choice but to implement countermeasures.' 'China has repeatedly expressed through bilateral dialogues that it is willing to properly handle differences with the EU through dialogue and consultation and bilateral government procurement arrangements,' said a statement from a spokesman with the Ministry of Commerce. 'Unfortunately, the EU has ignored China's goodwill and sincerity and still insisted on taking restrictive measures and building new protectionist barriers.'
New York Times
an hour ago
- New York Times
Europe's Dilemma: Build a Military Industry or Keep Relying on the U.S.
European countries have committed to spending nearly double on military investments over the next decade, with high hopes that it will benefit their defense industries. But it is not clear that all that money — perhaps as much as 14 trillion euros, or $16 trillion — will fuel a flurry of high-end innovation in Europe. That is because of what one might call the F-35 problem. Europe lacks quality alternatives to some of the most needed and desired defense equipment that American companies produce. Among them is the F-35, Lockheed Martin's famed stealth fighter jet, whose advanced abilities are unmatched by European counterparts. Patriot missile-defense systems are also imported from America, as are rocket launchers, sophisticated drones, long-range artillery guided by satellite, integrated command and control systems, electronic and cyber warfare capabilities — along with most of the software required to run them. And because many European nations have already invested in American weapons, they want new purchases to remain compatible. The pledged investments have created a tension. Should European nations build their own military industry? Does the war in Ukraine and the threat of a militarized Russia allow that much lead-time? Or should they continue to invest, at least in part, in America's already available, cutting-edge technology? Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
